China · Delayed Price · Currency is CNY Guobang Pharma Statistics
Total Valuation
Guobang Pharma has a market cap or net worth of CNY 12.02 billion. The enterprise value is 10.25 billion.
| Market Cap | 12.02B |
| Enterprise Value | 10.25B |
Important Dates
The next estimated earnings date is Thursday, July 30, 2026.
| Earnings Date | Jul 30, 2026 |
| Ex-Dividend Date | May 29, 2026 |
Share Statistics
Guobang Pharma has 782.35 million shares outstanding. The number of shares has decreased by -1.78% in one year.
| Current Share Class | 782.35M |
| Shares Outstanding | 782.35M |
| Shares Change (YoY) | -1.78% |
| Shares Change (QoQ) | -0.50% |
| Owned by Insiders (%) | 12.69% |
| Owned by Institutions (%) | 16.78% |
| Float | 323.40M |
Valuation Ratios
The trailing PE ratio is 15.48.
| PE Ratio | 15.48 |
| Forward PE | n/a |
| PS Ratio | 1.97 |
| PB Ratio | 1.38 |
| P/TBV Ratio | 1.44 |
| P/FCF Ratio | 15.49 |
| P/OCF Ratio | 10.88 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.44, with an EV/FCF ratio of 13.21.
| EV / Earnings | 13.37 |
| EV / Sales | 1.68 |
| EV / EBITDA | 7.44 |
| EV / EBIT | 11.53 |
| EV / FCF | 13.21 |
Financial Position
The company has a current ratio of 2.54, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.54 |
| Quick Ratio | 1.70 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.72 |
| Debt / FCF | 1.28 |
| Interest Coverage | 32.33 |
Financial Efficiency
Return on equity (ROE) is 8.99% and return on invested capital (ROIC) is 11.06%.
| Return on Equity (ROE) | 8.99% |
| Return on Assets (ROA) | 4.94% |
| Return on Invested Capital (ROIC) | 11.06% |
| Return on Capital Employed (ROCE) | 10.07% |
| Weighted Average Cost of Capital (WACC) | 5.22% |
| Revenue Per Employee | 1.43M |
| Profits Per Employee | 180,304 |
| Employee Count | 4,251 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 2.89 |
Taxes
In the past 12 months, Guobang Pharma has paid 126.16 million in taxes.
| Income Tax | 126.16M |
| Effective Tax Rate | 14.18% |
Stock Price Statistics
The stock price has increased by +6.15% in the last 52 weeks. The beta is 0.22, so Guobang Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | +6.15% |
| 50-Day Moving Average | 16.98 |
| 200-Day Moving Average | 17.33 |
| Relative Strength Index (RSI) | 35.05 |
| Average Volume (20 Days) | 4,194,077 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Guobang Pharma had revenue of CNY 6.09 billion and earned 766.47 million in profits. Earnings per share was 0.99.
| Revenue | 6.09B |
| Gross Profit | 1.50B |
| Operating Income | 888.78M |
| Pretax Income | 889.60M |
| Net Income | 766.47M |
| EBITDA | 1.38B |
| EBIT | 888.78M |
| Earnings Per Share (EPS) | 0.99 |
Balance Sheet
The company has 2.77 billion in cash and 994.27 million in debt, with a net cash position of 1.77 billion or 2.26 per share.
| Cash & Cash Equivalents | 2.77B |
| Total Debt | 994.27M |
| Net Cash | 1.77B |
| Net Cash Per Share | 2.26 |
| Equity (Book Value) | 8.72B |
| Book Value Per Share | 11.14 |
| Working Capital | 3.96B |
Cash Flow
In the last 12 months, operating cash flow was 1.10 billion and capital expenditures -328.11 million, giving a free cash flow of 776.02 million.
| Operating Cash Flow | 1.10B |
| Capital Expenditures | -328.11M |
| Depreciation & Amortization | 487.86M |
| Net Borrowing | -7.84M |
| Free Cash Flow | 776.02M |
| FCF Per Share | 0.99 |
Margins
Gross margin is 24.60%, with operating and profit margins of 14.59% and 12.58%.
| Gross Margin | 24.60% |
| Operating Margin | 14.59% |
| Pretax Margin | 14.60% |
| Profit Margin | 12.58% |
| EBITDA Margin | 22.60% |
| EBIT Margin | 14.59% |
| FCF Margin | 12.74% |
Dividends & Yields
This stock pays an annual dividend of 0.43, which amounts to a dividend yield of 2.73%.
| Dividend Per Share | 0.43 |
| Dividend Yield | 2.73% |
| Dividend Growth (YoY) | 38.65% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 47.10% |
| Buyback Yield | 1.78% |
| Shareholder Yield | 4.48% |
| Earnings Yield | 6.38% |
| FCF Yield | 6.46% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 29, 2026. It was a forward split with a ratio of 1.4.
| Last Split Date | May 29, 2026 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Guobang Pharma has an Altman Z-Score of 4.61 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.61 |
| Piotroski F-Score | 7 |